| Trial | Updated / Type |
Status | Phase | Were Results Reported |
Reported Actual Enrollment |
(MeSH) Terms |
Why Stopped
Limitations And Caveats |
Annotator decisions |
|---|---|---|---|---|---|---|---|---|
| NCT04160195 Details | 2022-02-15 Interventional | 1 | 2 | Cyclophosphamid… Fludarabine Hodgkin Disease Leukemia Leukemia, Lymph… Leukemia, Lymph… Lymphoma Lymphoma, B-Cel… Lymphoma, Non-H… B-Cell Chronic … Chronic Lymphoc… Lymphoma, Non-h… | The original principal investigator left the National Institutes of Health (NCI) and the
decision was made to close the study to enrollment. - | |||
| NCT00449111 Details | 2022-02-15 Interventional | 3 | 11 | Losartan Essential Hyper… Hypertension | - - | |||
| NCT04501211 Details | 2022-02-14 Interventional | 2 | 0 | Granisetron Gastroparesis | Abandoned due to limited resources - | |||
| NCT02678143 Details | 2022-02-14 Interventional | 1 | 1 | Alemtuzumab Cyclophosphamid… Fludarabine Mycophenolic Ac… Sirolimus Anemia, Sickle … Sickle Cell Dis… | Closed early due to competing studies - | |||
| NCT00540839 Details | 2022-02-14 Interventional | 3 | 0 | Fluticasone Montelukast Xhance Asthma Asthma, Bronchi… | Based on input from regulatory agencies, it is not necessary to conduct this study. An ongoing
study was sufficient for regulatory purposes. - | |||
| NCT02348359 Details | 2022-02-11 Interventional | 2 | 157 | Aflibercept Ranibizumab Eye Diseases Macular Degener… Retinal Degener… Retinal Disease… AMD Age-Related Mac… Exudative Age-r… Macular Degener… | Interim analysis found study had achieved primary objective - | |||
| NCT05042934 Details | 2022-02-10 Interventional | 1/2 | 0 | Camptothecin Irinotecan Sarcoma Sarcoma, Ewing Metastatic Ewin… Recurrent Ewing… | PI stated trial no longer fits the framework & portfolio of work that is prioritized by the
department. PI will not have the anticipated accrual in PI view to complete the study. Given
that, PI request this protocol be closed prior to its activation. - | |||
| NCT04608266 Details | 2022-02-10 Interventional | 3 | 70 | Camostat COVID-19 Covid19 | Scientific committee decision due SARS-CoV2 pandemic evolution with a decrease in inclusions
and widespread distribution of vaccines - | |||
| NCT04928950 Details | 2022-02-09 Interventional | 2 | 0 | Charcoal Lung Neoplasms Lung Cancer | Because of logistic challenges and lack of product among other factors, we decided to
completely withdrawn this study. - | |||
| NCT02895373 Details | 2022-02-09 Interventional | 2 | 50 | Alprostadil Acute Lung Inju… Respiratory Dis… Respiratory Dis… Extracorporeal … Respiratory Dis… | After completion of pilot study (n=50) no effect on primary outcome and limited feasibility of
recruitment and study procedures - | |||
| NCT00447603 Details | 2022-02-09 Interventional | 3 | 40 | Hydrochlorothia… Losartan Hypertension | Achieving site readiness and enrolling the trial within a reasonable time The study was discontinued early (during screening) due to limited availability of sites and readiness of sites to enroll participants within the predefined time. | |||
| NCT05008510 Details | 2022-02-08 Interventional | 2 | 0 | Camptothecin Immunoconjugate… Sacituzumab gov… Breast Neoplasm… Triple Negative… Metastatic Trip… | Decided to halt and will potentially reopen in the future. - | |||
| NCT04119830 Details | 2022-02-08 Interventional | 2 | 0 | Pembrolizumab poly(I).poly(c1… Adenocarcinoma Colorectal Neop… Metastatic Colo… Microsatellite … Mismatch Repair… Refractory Colo… Stage III Color… Stage IIIA Colo… Stage IIIB Colo… Stage IIIC Colo… Stage IV Colore… Stage IVA Color… Stage IVB Color… Stage IVC Color… Unresectable Co… | implementation issues - | |||
| NCT03912350 Details | 2022-02-08 Interventional | 1 | 0 | Balovaptan Autism Spectrum… | The study is on hold due to stopping of the Autism Spectrum Disorder program with balovatpan,
the study drug. - | |||
| NCT02354547 Details | 2022-02-08 Interventional | 1 | - | Cyclophosphamid… Topotecan Neoplasm | - - | |||
| NCT03099486 Details | 2022-02-07 Interventional | 2 | 2 | Leucovorin Colorectal Neop… Colorectal Canc… | Administrative change - | |||
| NCT01336530 2009-014441-93 Details | 2022-02-07 Interventional | 3 | 40 | Aluminum Hydrox… Antacids Magnesium Hydro… Oxethazaine Esophagitis Radiation-induc… | The study stopped prematurely due to and administrative reasons, not based on grounds of
safety. - | |||
| NCT00408473 Details | 2022-02-07 Interventional | 4 | - | Flecainide Atrial Fibrilla… | - - | |||
| NCT04898309 Details | 2022-02-04 Interventional | 2/3 | 0 | Complement C1 I… Complement C1 I… Complement C1s Angioedema Angioedemas, He… Hereditary Angi… | Company pipeline revision - | |||
| NCT03882918 Details | 2022-02-04 Interventional | 3 | 125 | Gaboxadol Angelman Syndro… Syndrome | Company decision - |